Ondax

Ondansetron

Method of action: Anti-Abstinence, Antiemetic

Treatment option: Acute Nausea And Vomiting, Cancer, Burping, Morning Sickness, Chemotherapy

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ondax

Quick Facts

Property	Description
Active ingredient	Ondansetron
Form	Tablet, Oral Solution, Injection, ODT
Pharmacological class	Selective Serotonin 5-HT3 Receptor Antagonist
Common use	Prevention and relief of nausea and vomiting
Origin	Synthetic Tryptamine Derivative

Ondax is a pharmaceutical product whose active ingredient is Ondansetron, a medicine specifically designed to counteract the body's natural reflex to vomit. It is formally classified as an antiemetic agent, targeting the central and peripheral pathways that initiate nausea. The drug's therapeutic aim is to provide effective relief and prevention for symptoms of nausea and vomiting across various clinical situations, such as those associated with certain medical procedures.

What is Ondax and Its Pharmacological Identity?

Ondax, based on the nonproprietary active substance Ondansetron, is a selective serotonin 5-HT3 receptor antagonist. This compound is a synthetic tryptamine derivative, establishing it as a highly specialized agent within the field of antiemetic therapy. Its function is to interfere with the signaling of Serotonin, a key chemical messenger that triggers the emetic response both in the gastrointestinal tract and in the central nervous system's vomiting control center. Its primary mechanism involves blocking the actions of serotonin at the 5-HT3 receptors. This means the medicine is clinically recognized for its ability to specifically block one of the body's main chemical signals for the urge to vomit.

Composition and Available Pharmaceutical Forms

The core composition of Ondax is the single active ingredient, Ondansetron, typically supplied as the hydrochloride dihydrate salt combined with various inactive solid or liquid excipients. This single-entity formulation contrasts with combination antiemetic products. Ondax is manufactured in several standard dosage forms to accommodate different patient needs, including film-coated tablets, rapidly dissolving oral disintegrating tablets (ODT), oral solutions, and sterile solutions for injection suitable for parenteral use. The availability of these various forms, including those for the oral and parenteral routes, ensures the medicine can be delivered even when a patient is actively vomiting or requires fast relief.

The Purpose of Ondansetron: Focused Nausea Relief

The general purpose of Ondansetron is to manage and prevent the onset of nausea and vomiting by intervening in the specific chemical cascade responsible for these symptoms. By utilizing its highly selective antagonism of the 5-HT3 receptor, the drug prevents the nervous system from relaying critical signals to the brain that would otherwise trigger the physical act of vomiting. This action provides relief that is chemically targeted, supporting the body's ability to maintain calm and control over the emetic reflex.

What side effects are possible with Ondax?

Possible side effects and safety information

The official safety documentation for Ondansetron, the active ingredient in Ondax, organizes potential adverse reactions by frequency and the body's physiological systems involved, as classified by regulatory authorities like the FDA and EMA.

Frequency and System-Organ Classifications

Adverse reactions are classified into frequency tiers based on clinical data:

Very Common (Affecting ge 1 in 10 patients): Headache.
Common (Affecting ge 1 in 100 to <1 in 10 patients): Constipation and a sensation of warmth or flushing.
Uncommon (Affecting ge 1 in 1,000 to <1 in 100 patients): These include reactions affecting the Nervous System (e.g., seizures, extrapyramidal movement disorders) and the Cardiac System (e.g., arrhythmias, chest pain, hypotension, and asymptomatic increases in liver function tests).
Rare to Very Rare (Affecting <1 in 1,000 patients): Reactions affecting the eyes, such as transient visual disturbances and transient blindness, have been reported, primarily during rapid intravenous administration. Immediate hypersensitivity reactions, including anaphylaxis, are also officially documented.

Serious Adverse Reactions and Safety Constraints

The regulatory profile highlights specific serious risks. The medicine carries a formal warning regarding its potential to cause QTc prolongation and related cardiac arrhythmias, such as Torsade de Pointes. Serotonin Syndrome has been documented, particularly with co-administration of other serotonergic medicines. Myocardial ischemia has been reported in the post-marketing setting.

Official labeling includes specific safety constraints. Ondansetron is contraindicated for use with apomorphine due to the documented risk of profound hypotension and loss of consciousness. Caution is warranted in patients with pre-existing cardiac conditions (e.g., electrolyte imbalances, congestive heart failure) and those with signs of subacute intestinal obstruction.

Population Safety Notes

Safety data indicates that the medicine's clearance is significantly reduced and its half-life prolonged in individuals with moderate or severe hepatic impairment. For older adults, while no alteration in dosing frequency is typically required, a greater effect on the heart's QTc interval is predicted in patients ge 75 years of age. The adverse event profile in the pediatric population (aged ge 6 months) is considered comparable to that of adults.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose with Ondax requires immediate medical attention. This need for urgent help is based on the documented potential for severe manifestations affecting the cardiovascular and central nervous systems, as stated in official regulatory labeling.

Officially Documented Manifestations

Overdose exposure is formally associated with dose-dependent QT interval prolongation, a significant cardiac finding. Other documented presentations include seizures (tonic-clonic type), bradyarrhythmia (slow heart rate), and hypotension. Less common, but officially noted, are transient ocular effects such as temporary blindness.

Life-Threatening Risks

The regulatory profile explicitly notes the potential for Torsade de Pointes, a serious heart rhythm disorder, in post-marketing cases. Additionally, the risk of developing Serotonin Syndrome is documented, which can occur with overdose or when Ondansetron is combined with other serotonergic agents. Due to these risks, medical monitoring, including ECG monitoring, is recommended following any suspected overdose.

Required Emergency Actions

Regulatory documents state that no specific antidote is known for Ondansetron overdose. Therefore, treatment focuses on providing appropriate symptomatic and supportive therapy. Patients must seek urgent medical assistance immediately upon suspicion of an overdose. Specific caution is noted for patients with severe hepatic impairment due to reduced clearance, increasing the potential for toxicity, and for patients with congenital long QT syndrome, where use is strictly avoided.

Therapeutic Uses of Ondax

What Ondax Treats: Main Uses and Benefits

Supportive Care for Cancer Treatment Side Effects

Ondax is commonly used in situations involving certain distressing symptoms caused by cancer therapies. It is applied to manage the nausea and vomiting associated with both highly emetogenic and moderately emetogenic chemotherapy regimens, as well as those symptoms arising from focused radiation therapy to the abdomen. The medication helps manage symptom clusters that may become intense or disruptive during or shortly after treatment, and supports patients during difficult episodes by easing distress.

Preventing Nausea in Post-Surgical Recovery

The medication is commonly used across conditions presenting with acute episodes, specifically to prevent Postoperative Nausea and Vomiting (PONV). It is relevant in clinical settings marked by increased discomfort following general anesthesia, where symptoms that create noticeable physiological strain are a concern. This short-term symptomatic assistance contributes to improved comfort during periods of heightened symptoms and assists with maintaining comfort during periods of symptomatic fluctuation, supporting the patient during episodes of difficult post-surgical recovery.

Quick Fact: Relief for Acute Emetic Symptoms
Primary Therapeutic Goal	Prevention and management of nausea and vomiting.
Target Conditions	Postoperative nausea, Chemotherapy-Induced Nausea, Radiation-Induced Nausea.
Benefit Focus	Easing overall symptom burden and supporting functional stability.

Regulatory References

Ondansetron oral solution DailyMed - NIH

Eligibility and Restrictions for Use

Who Can and Cannot Use Ondax? (Ondansetron)

Official regulatory information strictly defines the populations permitted, restricted, or prohibited from using this medicine.

Contraindications (Must Not Use)

Category	Prohibited Populations
Absolute Prohibition	Patients with known hypersensitivity to Ondansetron. Patients receiving concomitant apomorphine.
Specific Conditions	Individuals with congenital long QT syndrome (due to cardiovascular risk).

Age and Physiological Eligibility

Category	Regulatory Status
Pediatric Use	Use for CINV is established in children six months of age and older. For PONV, use is established in infants one month of age and older.
Pregnancy	Not recommended during the first trimester of pregnancy.
Lactation	Use is conditional; a choice must be made to discontinue the medicine or discontinue nursing.

Conditional Use and Restrictions

Patients with severe hepatic impairment are permitted to use Ondax only with a mandated maximum total daily dose reduction. For patients with any degree of renal impairment, no dosage adjustment is required. Caution is necessary for patients with, or at risk of, QT prolongation or those with signs of subacute intestinal obstruction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes interactions of the active ingredient Ondansetron as documented in official government regulatory information.

Interaction Scope

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions	Serotonergic drugs, QT-prolonging medicines, Potent CYP3A4 inducers.
Specific interacting medicines (if explicitly listed)	Apomorphine (contraindicated), Phenytoin, Carbamazepine, Rifampin, Tramadol, Aprepitant.
Mechanistic basis of interactions	Pharmacokinetic interaction via CYP3A4, CYP2D6, and CYP1A2 metabolism. Pharmacodynamic interaction (additive cardiac effects, enhanced serotonergic activity).
Interaction-related restrictions	Strict prohibition of co-administration with Apomorphine. Avoidance with Congenital Long QT Syndrome.

Official Interaction Statements

The co-administration of Apomorphine is explicitly contraindicated due to documented reports of profound hypotension and loss of consciousness.
Co-administration with potent CYP3A4 inducers significantly increases the clearance of Ondansetron, resulting in decreased plasma concentrations.
Concomitant use with other serotonergic drugs has been associated with reports of Serotonin Syndrome.
Co-administration with other QT-prolonging medicines may increase the risk of QT interval prolongation.
The clearance of Ondansetron is substantially decreased and the half-life is prolonged in patients with severe hepatic impairment.

Regulatory documents establish a formal interaction profile defined by one mandatory contraindication and two major mechanisms: pharmacokinetic modification by CYP inducers and pharmacodynamic augmentation of cardiac and neurological risks. This structure identifies specific drug classes and physiological states that officially alter the disposition or safety profile of the medicine. The official labeling also notes that no mandatory time-separation rules are documented.

Mechanism of Action

The mechanism of action for Ondansetron involves a targeted, dual-point blockade of Serotonin signaling within pathways that propagate afferent emetic impulses.

Suppression of Serotonin Signaling in the Gastrointestinal Tract

This domain covers the drug's action on the peripheral mathbf5 -HT3 receptors located on the vagal nerve endings in the gut wall. By acting as a selective antagonist, the drug blocks the abundant Serotonin released by the gut (e.g., in response to certain chemical stimuli) from binding to these receptors. This mechanism blocks the mathbf5 -HT3 receptor-mediated depolarization of afferent vagal nerves, altering the transmission of GI signals toward the central nervous system ( CNS).

Central Blockade of the Chemoreceptor Trigger Zone (CTZ)

The second key domain involves the drug's activity in the brainstem, specifically at the CTZ. The CTZ monitors the bloodstream for chemical stimuli that activate 5 -HT3 receptors. Ondansetron blocks the 5 -HT3 receptors within this central zone, suppressing signal transduction by circulating mediators. This dual central and peripheral suppression of the mathbf5 -HT3 pathway leads to inhibition of Vomiting Center activation.

Dosage and Administration Information

Ondax (Ondansetron) administration follows established protocols that specify the required route, dose, and timing. The medicine is manufactured for oral use in forms such as tablets, oral solutions, and oral disintegrating tablets (ODTs), as well as for parenteral delivery via intravenous (IV) or intramuscular (IM) injection.

The specific dose and route are determined by the clinical context but generally follow a prophylactic schedule, meaning administration occurs before the emetogenic stimulus. For patients undergoing highly emetogenic chemotherapy (HEC), the standard oral regimen involves a single 24 mg dose administered 30 minutes prior to treatment. For the prevention of postoperative nausea and vomiting (PONV), a single 4 mg dose is commonly administered intravenously or intramuscularly immediately before or after surgery.

Use is typically short-term, with oral regimens for chemotherapy sometimes continuing for 1 to 2 days after the initial treatment to manage delayed effects. Official administration instructions state that oral forms may be taken with or without food. For IV administration in chemotherapy, dilution of the solution is required, and doses should be infused over 15 minutes.

Dosing requires modification for specific populations: patients with severe hepatic impairment must not exceed a total daily dose of 8 mg. No dose adjustment is generally specified for older adults or individuals with renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ondax (Ondansetron)

This overview describes the types of clinical studies that have been conducted on Ondansetron for its approved uses. It focuses on what researchers have explored and monitored, without making claims about effectiveness or offering personal medical advice.

Evidence for Preventing Nausea from Chemotherapy

Ondansetron was studied for its role in managing outcomes related to systemic or functional imbalance associated with cancer treatment, an instance of conditions involving periods of heightened symptoms. The research primarily consists of Randomized Controlled Trials (RCTs). These trials research examined different chemotherapy regimens, categorizing them based on their likelihood to cause these specific symptoms.

Studies report measurements for Complete Response, which tracked the absence of vomiting episodes and no use of rescue medication. Research explored whether Complete Response patterns were observed in combination use with other agents in the trials. Research explored short-term symptom changes within the first day following chemotherapy, as well as the patterns of symptoms that may appear over the next four days.

Evidence for Acute vs. Delayed Symptoms

The clinical trials research describes the patterns of nausea and vomiting in two specific timeframes. The acute phase covers the initial 24 hours immediately after chemotherapy, where trials typically monitored the frequency of immediate vomiting episodes. The delayed phase covers the subsequent four days (up to 120 hours). Research indicates that the measurements for symptoms were observed in some studies to be less consistent in the delayed phase than in the acute phase.

Evidence for Preventing Postoperative Nausea and Vomiting (PONV)

Ondansetron was evaluated in numerous RCTs and synthesis reports (meta-analyses) focusing on conditions characterized by fluctuating or episodic manifestations following surgery performed under general anesthesia. The research examined outcomes related to physical discomfort, specifically the occurrence of nausea and vomiting in the hours after the procedure.

Study Duration and Extended Follow-up

Most of the core clinical trials for Ondansetron were observed in the short-term, typically covering just the first 24 to 48 hours after surgery or the first five days after chemotherapy. Therefore, the follow-up durations were limited. Currently, there is limited information for long-term outcomes regarding the continued need for this medication.

What is Still Uncertain About Ondansetron Evidence

Research has shown that the evidence specifically related to the measurement of the subjective feeling of nausea alone is limited. Findings often suggest that the measurement of the absence of vomiting was less variable than the measurement of the subjective feeling of nausea.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Ondax (FAQ)

Q: Is Ondax a prescription-only medicine?

Yes, regulatory status confirms that the medicine is available only by prescription (Rx-only) in major markets like the U.S. and Europe. The drug's legal status requires a prescription from a licensed healthcare provider.

Q: What is the difference between Ondax and other medicines for the same condition?

Ondax is defined by its selective mechanism of action. It belongs to the pharmacological class of selective Serotonin 5 -HT3 receptor antagonists. This specificity means it only targets one specific chemical pathway (Serotonin signaling) to control the vomiting reflex.

Q: Is Ondax the same type of drug as [Similar Drug Name]?

The active ingredient in Ondax, Ondansetron, is classified as a selective Serotonin 5 -HT3 receptor antagonist. This classification means it is a highly specialized antiemetic that only targets this specific serotonin signaling pathway to control the vomiting reflex.

Q: What does 'contraindicated' mean in relation to Ondax?

'Contraindicated' is a strict regulatory term describing a situation where the medicine is officially not recommended for use under specific conditions, such as having a pre-existing medical condition or taking a certain other medicine (like apomorphine). Regulatory bodies mandate this prohibition when the documented risk of use clearly outweighs any possible benefit.

Q: Are drug interactions with Ondax usually severe or minor?

The documented drug interactions of Ondax are associated with serious potential risks. These risks include the potential for life-threatening Serotonin Syndrome, QTc prolongation (an electrical heart issue), and profound hypotension (severely low blood pressure) when co-administered with specific forbidden medicines.

Q: Is Ondax addictive or habit-forming?

According to official regulatory classifications, Ondax is not a controlled substance. Therefore, it is not generally associated with drug abuse or dependence.

Q: What is the risk classification of Ondax?

Ondax is classified as a prescription-only (Rx-only) medicine in major regulatory markets. It is not classified as a controlled substance under federal drug schedules.

Q: Do studies suggest Ondax is effective for everyone who uses it?

Studies track outcomes such as the Complete Response, defined as the absence of vomiting and the need for rescue medication. However, official research reports acknowledge that the effect of the medicine can vary between individuals and across different timeframes of symptoms (acute versus delayed).

Q: Is it normal to feel no difference right after starting Ondax?

Official documents indicate that Ondax is often administered preventatively (prophylactically). Clinical trials primarily measure the Complete Response, which is the absence of vomiting. Therefore, the medicine’s therapeutic focus is the prevention of symptoms, which may not result in an immediate subjective feeling of difference after administration.

Q: How quickly does Ondax typically start to work?

Official information describes that administration of the medicine typically occurs up to 30 minutes before certain procedures or treatments. However, regulatory documents do not specify a precise time frame for a patient to feel the onset of its anti-nausea effect.

Q: Does Ondax have an immediate effect or does it build up over time?

Ondax is described as being rapidly absorbed into the body. However, its effectiveness relies on its preventative action, meaning it is administered to block the nausea signal before it starts, rather than requiring several days of dosing to reach its initial full effect.

Q: How long does the general effect of one dose of Ondax last?

Pharmacokinetic data from official sources describes the elimination half-life of the active ingredient in healthy adults as approximately 5.7 hours. The half-life is the time it takes for the concentration of the medicine in the blood to reduce by half.

Q: Does Ondax generally make people feel tired?

Safety reports from clinical trials indicate that common side effects can include fatigue and malaise (a general feeling of discomfort or illness). These are noted in the official documentation describing possible systemic reactions.

Q: Can Ondax cause issues with sleep or alertness?

Official safety reports list both drowsiness/sedation and sleep disturbance as documented side effects. These effects vary in frequency depending on the condition being treated and are noted in the medicine's safety profile.

Q: Does Ondax change your mood or behavior?

Official safety reports indicate that psychiatric side effects, including agitation, anxiety, and sleep disturbance, have been documented, although they are generally uncommon. These effects are noted in the safety profile describing possible nervous system reactions.

Q: Is it safe to drive or operate machinery while using Ondax?

Official safety documents list side effects that may affect the nervous system, such as dizziness, seizures, and transient visual disturbances. These types of reactions could potentially impair a person's ability to drive or use complex machinery.

Q: What common over-the-counter pain relievers interact with Ondax?

Official regulatory information alerts that using Ondax with other serotonergic drugs can increase the risk of a serious condition called Serotonin Syndrome. This category of interacting medications may include certain over-the-counter pain relievers. The Interactions section provides official descriptions of the specific drug classes involved.

Q: Can vitamins or herbal supplements interfere with Ondax?

Official prescribing information notes that potent inducers of a liver enzyme called CYP3A4 can increase the clearance of the medicine and decrease the amount of the active ingredient in the blood. This group of substances may include certain herbal products or supplements.

Q: Do you need to avoid alcohol completely while taking Ondax?

Regulatory documents do not list a specific interaction between the medicine and alcohol. However, it is noted that alcohol consumption may independently worsen the underlying nausea and vomiting symptoms the medicine is intended to prevent.

Q: Can Ondax be used with common blood pressure medications?

Official prescribing information highlights the need for caution when the medicine is used with other medications that can affect the heart's electrical activity, specifically the QT interval. This category of medicines includes some commonly prescribed cardiovascular or blood pressure treatments.

Q: What should I do if I get a rash while using Ondax?

Official safety warnings document rare to very rare cases of immediate hypersensitivity reactions, which can include rash, hives, and anaphylaxis. Hypersensitivity is noted as a serious potential reaction in the medicine's safety profile.

How should Ondax be stored and disposed of?

Official Storage and Disposal Requirements

Storage and handling rules for Ondansetron (Ondax) are mandated by its pharmaceutical form to maintain product quality and safety, and must be followed strictly.

Formulation	Required Storage Condition	Stability Constraint
Tablets	Controlled Room Temperature (20 C to 25 C) in tight, light-resistant containers	Keep in original sealed packaging
Oral Solution	Stored upright and not above 25 C	Must be used within 28 days after first opening
Injection	Between 2 C and 30 C (36 F to 86 F), protected from light	Diluted solution must not be used beyond 24 hours

All forms of this medicine must be kept out of the sight and reach of children. The oral solution must not be refrigerated or frozen. Unused product or waste material must be disposed of in accordance with local requirements, and medicines should not be disposed of via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Colombia

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z